Reported 0 shares, down 15 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2022-09-30 | 0 |
| 2022-12-31 | 305 |
| 2023-03-31 | 7 |
| 2023-06-30 | 12 |
| 2023-09-30 | 5 |
| 2023-12-31 | 222 |
| 2024-03-31 | 7 |
| 2024-06-30 | 4 |
| 2024-09-30 | 27876 |
| 2024-09-30 | 0 |
| 2024-12-31 | 0 |
| 2025-12-31 | 42080 |
| 2026-03-31 | 4621 |
| 2026-06-30 | 5079 |
| 2026-09-30 | 4567 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Unchanged | 20,299 | 0 (0.0%) | < 0.01% | $4,567 | 2026-11-13 | |
| Q2 2026 | Reduced | 20,299 | -3,303 (-14.0%) | < 0.01% | $5,079 | 2026-08-13 | |
| Q1 2026 | Reduced | 23,602 | -176,398 (-88.2%) | < 0.01% | $4,621 | 2026-05-15 | |
| Q4 2025 | New | 200,000 | +200,000 (0.0%) | < 0.01% | $42,080 | 2026-02-13 | |
| Q4 2024 | Reduced | 0 | -20,200 (-100.0%) | 0 | $0 | 2025-02-14 | |
| Q3 2024 | Reduced | 0 | -15 (-100.0%) | 0 | $0 | 2024-11-14 | |
| Q3 2024 | New | 20,200 | +20,200 (0.0%) | < 0.01% | $27,876 | 2024-11-14 | |
| Q2 2024 | Unchanged | 15 | 0 (0.0%) | < 0.01% | $4 | 2024-08-14 | |
| Q1 2024 | Reduced | 15 | -500 (-97.1%) | < 0.01% | $7 | 2024-05-15 | |
| Q4 2023 | Added | 515 | +505 (5050.0%) | < 0.01% | $222 | 2024-02-13 | |
| Q3 2023 | Reduced | 10 | -2 (-16.7%) | < 0.01% | $5 | 2023-11-15 | |
| Q2 2023 | Added | 12 | +2 (20.0%) | < 0.01% | $12 | 2023-08-14 | |
| Q1 2023 | Reduced | 10 | -661 (-98.5%) | < 0.01% | $7 | 2023-05-15 | |
| Q4 2022 | Added | 671 | +373 (125.2%) | < 0.01% | $305 | 2023-02-14 | |
| Q3 2022 | New | 298 | +298 (0.0%) | 0 | $0 | 2022-11-14 |
Who else reported the position
21 managers reported THERIVA BIOLOGICS INC for Q3 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| IFP Advisors Inc | Added | 296 | +284 | < 0.01% | $43 | 8 qtrs |
| FMR LLC | Reduced | 0 | -500 | 0 | $0 | 5 qtrs |
| Bank of America Corporation | Reduced | 0 | -146 | 0 | $0 | 9 qtrs |
| Tower Research Capital LLC TRC | Reduced | 0 | -145 | 0 | $0 | 9 qtrs |
| WELLS FARGO & COMPANY MN | Reduced | 0 | -100 | 0 | $0 | 9 qtrs |
| Planning Capital Management Corp | Reduced | 0 | -110 | 0 | $0 | 2 qtrs |
| TWO SIGMA SECURITIES LLC | Reduced | 0 | -61,023 | 0 | $0 | 5 qtrs |
| CONCOURSE FINANCIAL GROUP SECURITIES INC | Unchanged | 0 | 0 | 0 | $0 | 9 qtrs |
| MSD Partners L P | Reduced | 0 | -598,411 | 0 | $0 | 2 qtrs |
| BLAIR WILLIAM & CO IL | Reduced | 0 | -10,153 | 0 | $0 | 4 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2024
- Filed
- November 14, 2024
- Filing type
- 13F-HR
- Position type
- COM NEW
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.